News
Results from Cognition's SHINE study, which enrolled individuals with mild-to-moderate Alzheimer's, were discussed with the ...
Mitolyn is a natural weight loss supplement designed to target a hidden cause of stubborn fat—poor mitochondrial health. Based on Harvard research ...
The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...
18h
MarketBeat on MSNAre Growth Stocks Back? 3 That Look Like Winners to Buy NowIn today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...
In a move that raises questions about its future role and composition, HHS Secretary Robert F. Kennedy Jr.'s office has called off a scheduled meeting of the U.S. Preventive Services Task Force. The ...
US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results